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a b s t r a c t
Analysis of the herpes simplex virus-1 (HSV-1) genome reveals two candidate p53 responsive elements
(p53RE), located in proximity to the replication origins oriL and oriS, referred to as p53RE-L and p53RE-S,
respectively. The sequences of p53RE-L and p53RE-S conform to the p53 consensus site and are present
in HSV-1 strains KOS, 17, and F. p53 binds to both elements in vitro and in virus-infected cells. Both
p53RE-L and p53RE-S are capable of conferring p53-dependent transcriptional activation onto a
heterologous reporter gene. Importantly, expression of the essential immediate early viral transactivator
ICP4 and the essential DNA replication protein ICP8, that are adjacent to p53RE-S and p53RE-L, are
repressed in a p53-dependent manner. Taken together, this study identiﬁes two novel functional p53RE
in the HSV-1 genome and suggests a complex mechanism of viral gene regulation by p53 which may
determine progression of the lytic viral replication cycle or the establishment of latency.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The genome of human herpes simplex virus-1 (HSV-1) is a
linear double-stranded DNA of 152-kbp containing two types of
DNA replication origin: one copy of oriL, located within the unique
long region, and two copies of oriS, located in the c repeats
ﬂanking the unique short region (Boehmer and Lehman, 1997).
oriL is ﬂanked by the promoters of the essential DNA replication
genes UL29 and UL30, encoding the single-strand DNA binding
protein (ICP8) and DNA polymerase, respectively. In contrast, oriS
is ﬂanked by the promoters of the immediate early (IE) genes ICP4
and ICP22 or ICP47, that are critical for the viral life cycle (Rajcani
and Durmanova, 2000). Although the functions of many HSV-1
gene products have been extensively studied, the molecular
mechanisms governing their expression are not fully understood,
particularly their differential regulation during lytic replication
and latency.
Human p53 is a phospho-protein composed of several struc-
tural and functional domains, including an N-terminal transactiva-
tion domain, a central DNA-binding domain, a tetramerization
domain, and a C-terminal regulatory domain (Somasundaram and
El-diery, 2000). Biochemically, p53 acts as a transcription factor
capable of mediating both activation and repression of gene
expression. p53 tetramers bind to speciﬁc DNA elements in the
promoter regions of target genes leading to activation or repres-
sion of gene expression (Riley et al., 2008). Crystallographic
analysis has revealed a loop–sheet–helix motif and two large
loops within the DNA-binding domain of p53 that mediate
interactions with both the major and minor grooves of DNA (Cho
et al., 1994). Binding of p53 to DNA occurs either after post-
translational modiﬁcation or when it forms a complex with other
essential nuclear proteins (Funk et al., 1992). Expression of p53 is
induced in response to diverse stimuli including: DNA damage,
hypoxia, oncogene activation, and viral infection, whereupon it
executes a plethora of functions to control the dynamic pattern of
gene expression required for maintaining a normal cell-cycle
(Beckerman and Prives, 2010). Biologically, p53 functions as a
tumor suppressor, acting as the “guardian of the genome” (Lane,
1992) and the “cellular gatekeeper” (Levine, 1997) by regulating a
number of downstream target genes involved in cell-cycle regula-
tion, DNA repair, cell–cell interaction, immune response, and
apoptosis (Collot-Teixeria et al., 2004). Despite these important
roles, mutations in p53 are not lethal (Donehower et al., 1992).
Rather, p53 mutations are the most common genetic abnormality
found in human cancer including colon, breast, and lung cancers
(Levine, 1993). Through its multiple actions, p53 has also been
documented to be a key regulator of viral infections (Lazo and
Santos, 2011).
Earlier studies have shown that p53 is not only recruited to
nuclear HSV-1 DNA replication compartments, but also co-
localizes with the essential viral DNA replication protein ICP8
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(Wilcock and Lane, 1991). This redistribution of p53 is speciﬁc,
since other host nuclear proteins including p68, lamin B, nucleo-
phosmin, and Ki67 do not redistribute during HSV-1 infection.
Also, Maruzuru et al. (2013) recently reported that p53 can play
both a positive and negative role in HSV-1 replication at different
stages by regulating ICP27 and ICP0 gene expression. However, the
molecular basis of these effects was not explored in their report.
These observations and the fact that p53 is a transcription factor
with DNA binding activity (Pavletich et al., 1993), prompted us to
hypothesize that a p53 responsive element(s) (RE) may exist in the
HSV-1 genome, allowing p53 to exert transcriptional control over
viral gene expression and/or DNA replication. Therefore, in this
study, we sought to identify p53RE in the HSV-1 genome. Here we
identify two candidate p53RE, located in the vicinity of the HSV-1
DNA replication origins oriL and oriS. Further, we show that p53
binds to both these sites in vitro and in vivo. In addition, we
demonstrate that these novel p53RE can confer transcriptional
control onto a heterologous reporter gene. Importantly, we ﬁnd
that p53 affects the expression of two essential viral proteins (ICP4
and ICP8) that are adjacent to these p53RE. The presence of
functional p53RE in the HSV-1 genome has implications for a
direct role of p53 in controlling HSV-1 replication.
Results
Identiﬁcation of two putative p53-responsive elements in the HSV-1
genome
To test the hypothesis that p53 may directly interact with the
HSV-1 genome via p53RE to potentially control viral gene expres-
sion and/or DNA replication, we performed an in silico search for
conserved p53 binding sites in the HSV-1 genome. The consensus
p53RE contain two copies of a 10 bp binding motif 50-RRRC(A/T)(T/
A)GYYY, in which the core motif is underlined and R is a purine
and Y is a pyrimidine, separated by a spacer of 0–13 bp (EI-Deiry
et al., 1992). These binding motifs can occur as direct or inverted
repeats, which dictates the symmetry with which the p53 tetra-
mer occupies the site (Ma et al., 2007). As shown in Fig. 1A, the
analysis revealed two candidate p53RE: one in the vicinity of oriL
and the other in the c repeats, in the vicinity of oriS, henceforth
designated p53RE-L and p53RE-S, respectively. In HSV-1 strain
KOS, p53RE-L is located at nucleotides 62608–62630, while the
two p53RE-S are located at nucleotides 131119–131144 and
146713–146738. The sequence of p53RE-L, 50-AAACAAGGCCcttG-
CACATGCCG, contains a pair of perfect 50-C(A/T)(T/A)G-30 p53RE
core motifs with a 3 bp spacer (indicated in lower case). In
contrast, the sequence of the two p53RE-S, 50-GAACTAGCGCg-
gaccGGTCGATGCTT, contains an extra G in the second core motif
and a 5 bp spacer. A precedent for an extra G exists in the p53RE of
the BCL6 promoter (Margalit et al., 2006). A detailed mapping of
the HSV-1 p53RE relative to the viral replication origin domains
and promoter elements is shown in Fig. 1A. Importantly, both
p53RE-L and p53RE-S are present in identical locations with 100%
sequence identity in HSV-1 strains F, 17 and KOS.
Fig. 1B shows a comparison and sequence alignment between
p53RE-L and p53RE-S and other well characterized p53RE, includ-
ing those associated with the HSV-1 TK (Yuan et al., 1993), BCL6
(Margalit et al., 2006), ABCA1 (Johnson et al., 2001), GADD45A
(Hollander et al., 1993), p21 (Saramäki et al., 2006), MDM2
(Zauberman et al., 1995), VDR (Maruyama et al., 2006), p73
(Chen et al., 2001), CASP6 (MacLachlan and El-Deiry, 2002), and
CASP10 (Rikhof et al., 2003) genes, and hepatitis B virus (Ori et al.,
1998). It should also be noted that albeit not the subject of the
current studies, our analysis indicates that candidate p53RE exist
in other herpesvirus family members including Varicella Zoster
Virus, Epstein Barr virus and cytomegalovirus (data not shown).
These ﬁndings, together with the reports cited above, suggest that
p53 may play a role in regulating HSV-1 replication. In this regard,
it is noteworthy to mention that the HSV-1 p53RE are ﬂanked by
important viral genes: in the case of p53RE-L the essential early
genes encoding the DNA polymerase (UL30) and ICP8 (UL29), and
in the case of p53RE-S the critical IE genes ICP4, and ICP22 or ICP47
(Fig. 1A).
p53 binds to HSV-1 p53RE in vitro and in vivo
Electrophoretic mobility shift assays (EMSA) were utilized to
examine the ability of p53 to bind 32P-labeled duplex oligonucleo-
tides containing the p53RE-L and p53RE-S sequences. The
GADD45A p53RE (50 GAACATGTCTAAGCATGCTG) were used as a
positive control. Initially, we evaluated the ability of puriﬁed
Escherichia coli expressed p53 to bind the probes. The results
show that puriﬁed p53 can indeed bind directly to the GADD45A,
p53RE-L and p53RE-S oligonucleotides (Fig. 2A, lanes 2, 4 and 6).
As indicated, two complexes, designated I and II, were formed
with GADD45A and p53RE-L while only complex II was evident
with p53RE-S. While these results do not address the afﬁnity with
which p53 interacts with these sites, they nevertheless demon-
strate that these sites are recognized in the absence of any other
co-factors and despite the fact that p53 may lack some of the
typical mammalian post-translational modiﬁcations that may
affect binding. Subsequently, to evaluate the recognition of these
sites by p53 in the context of any possible co-factors, we
performed EMSA with cell extracts. Hence, in order to obtain
functional p53 protein along with any necessary co-factors, p53
was overexpressed in mammalian COS-7 cells, followed by pre-
paration of whole cell lysates. Immunoblot analysis demonstrates
robust expression of p53 in both mock-transfected and to a higher
level in p53-transfected COS-7 cell lysates used for EMSA (Fig. 2B).
Fig. 2C shows that lysates incubated with the GADD45A p53RE,
p53RE-L and p53RE-S probes led to the formation of the same
complexes (I and II) observed with puriﬁed p53 (Fig. 2C, lanes 2, 6,
and 10). Notably, both complexes I and II were observed with
p53RE-S. To ascertain that complexes I and II contain p53, EMSA
was performed in the presence of p53-speciﬁc monoclonal anti-
bodies, either DO-1 or PAb1801, which recognize residues 11–25
and 32–79 of human p53, respectively. The addition of DO-1 had
no discernible effect on complexes I and II formation with either
GADD45A p53RE, p53RE-L or p53RE-S (Fig. 2C, lanes 3, 7, and 11).
In contrast, in the presence of PAb1801, complex I formation was
enhanced, whereas complex II formation was dramatically inhib-
ited with all three p53RE (Fig. 2C, lanes 4, 8, and 12). No apparent
ternary antibody–p53–DNA complex was formed with either
antibody as evidenced by the lack of a supershifted species. While
the formation of such ternary complexes is typically used to
evaluate the speciﬁcity of a protein–DNA complex, prior studies
with particular p53 antibodies support our ﬁndings that ternary
complexes may not form. Rather, consistent with our results,
studies with the Cdc25C and the 30-p21 p53RE found that
PAb1801 and PAb421 inhibited complex formation (Resnick-
Silverman et al., 1980), while p53 binding to the MDR1 promoter
p53RE was enhanced by PAb240, PAb246 and PAb1620 (Johnson
et al., 2001). Hence, our observation of speciﬁc PAb1801-induced
changes in the dynamics of complexes I and II formation demon-
strates that p53 is part of these complexes. Taken together, our
results indicate that p53 binds to both p53RE-L and p53RE-S, and
based on the formation of two complexes with varying sensitivity
to antibody, that the conformation of the p53 protomer on these
two elements may be different.
To further characterize the speciﬁcity of complexes I and II,
a competition assay was performed using unlabeled GADD45A,
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p53RE-L and p53RE-S oligonucleotides as speciﬁc competitors to
compete with the 32P-labeled probes for p53 binding. Complexes I
and II formed with GADD45A p53RE, p53RE-L or p53RE-S were all
markedly reduced by a 50-fold excess of each of the unlabeled
speciﬁc competitors (Fig. 2D, lanes 3–5, 8–10, and 13–15). Slight
differences were noted in the effectiveness of the three unlabeled
oligonucleotides when competing for binding with p53RE-L, with
the homologous p53RE-L being the most effective and the p53RE-S
being the least effective (compare Fig. 2D, lanes 8–10). EMSA was
also performed using radiolabeled p53RE-L and p53RE-S probes
containing C to A and G to T substitutions at both ends of the core
motif (50-C(A/T)(T/A)G-30). EMSA with these mutated p53RE dis-
played signiﬁcantly reduced complex formation (Fig. 2E, lanes 3, 4,
7, and 8), thus conﬁrming the speciﬁcity and crucial role of these
bases in the binding by p53. Together, the results indicate that p53
binds speciﬁcally to p53RE-L and p53RE-S.
We proceeded to examine whether p53 was capable of binding
to p53RE-L and p53RE-S in vivo in HSV-1-infected Vero cells using
ChIP assays. The results show that both p53RE sequences are
co-precipitated by the p53-speciﬁc antibody DO-1 antibody
(Fig. 3A, lanes 6 and 12), but not by normal rat IgG (Fig. 3A, lanes
5 and 11). No PCR product was detected in control precipitations
lacking antibody (Fig. 3A, lanes 1–3 and 7–9). In a further control
to demonstrate the speciﬁcity of p53 binding to p53RE-L and
p53RE-S, using a primer pair corresponding to a non-p53RE
containing region of the UL30 gene, no ampliﬁcation was detected
following immunoprecipitation with the DO-1 antibody (Fig. 3B).
Taken together, these results provide evidence that p53 binds to
p53RE-L and p53RE-S in HSV-1 infected cells.
p53RE-L and p53RE-S confer p53-dependent reporter gene activation
Since p53 binds to both p53RE-L and p53RE-S in vitro and
in vivo, these sequences might function to regulate viral gene
expression. To investigate whether p53RE-L and p53RE-S can
function as bonaﬁde p53RE, luciferase reporter gene vectors
were constructed that contain wild-type and mutant variants of
p53RE-L or p53RE-S. The mutations engineered into p53RE-L and
oriL oriSoriS
ICP22 ICP4UL30UL29 ICP4 ICP47
p53RE-S
AGACCCACGG ACCCCGACGA CCCCCGCCGT CGACGCGGAA
p53RE-L
AGGCACAGAT GCTTACGGTC AGGTGCTCCG GGTCGGGTGC
GTCTGGTATG CGGTTGGTAT ATGTACACTT TACCTGGGGG
CGTGCCGGTC CGCCCCAGCC CCTCCCACGC CCCGCGCGTC
CTAGCGCGGA CCGGTCGATG CTTGGGTGGG AAAAAGGACA
GGGACGGCCG ATCCCCCTCC CGCGCTTCGT CCGCGTATCG
GCGTCCCGGC GCGGCGAGCG TCTGACGGTC TGTCTCTGGC
GGTCCCGCGT CGGGTCGTGG ATCCGTGTCG GCAGCCGCGC
TCCGTGTGGA CGATCGGGGC GTCCTCGGGC TCATATAGTC
CCAGGGGCCG GCGGGAAGGA GGAGCAGCGG AGGCCGCCGG
ATCAGCCGGT GGGCGTGGCC GCTATTATAA AAAAAGTGAG
AACGCGAAGC GTTCGCACTT TGTCCTAATA ATATATATAT
TATTAGGACA AAGTGCGAAC GCTTCGCGTT CTCACTTTTT
TTATAATAGC GGCCACGCCC ACCGGCTACG TCACTCTCCT
GTCGGCCGCC GGCGGTCCAT AAGCCCGGCC GGCCGGGCCG
CCCCCCGCCC CCCCGGCGGG CCCACCCCGA ACGGAATTCC
ATTATGCACG ACCCCGCCCC GACGCCGGCA CGCCGGGGGC
CCGTGGCCGC GGCCCGTTGG TCGAACCCCC GGCCCCGCCC
ATCCGCGCCA TCTGCCATGG GCGGGGCGCG AGGGCGGGTG
GGTCCGCGCC CCGCCCCGCA TGGCATCTCA TTACCGCCCG
ACGCGAATAA ACCGGGCCGC CGGCCGGGGC GCCGCGCAGC
AGCTCGCCGC CCGGATCCGC CAGACAAACA AGGCCCTTGC
ACATGCCGGC CCGGGCGAGC CTGGGGGTCC GGTAATTTTG
ATCCGGCGGT TTCCGCTTCC GTTCCGCATG CTAACGAGGA
ACGGGCAGGG GGCGGGGCCC GGGCCCCGAC TTCCCGGTTC
GGCGGTAATG AGATACGAGC CCCGCGCGCC CGTTGGCCGT
CCCCGGGCCC CCCGGTCCCG CCCGCCGGAC GCCGGGACCA
ACGGGACGGC GGGCGGCCCA AGGGCCGCCC GCCTTGCCGC
CCCCCCATTG GCCGGCGGGC GGGACCGCCC CAAGGGGGCG
GGGCCGCCGG GTAAAAGAAG TGAGAACGCG AAGCGTTCGC
ACTTCGTCCC AATATATATA TATTATTAGG GCGAAGTGCG
AGCACTGGCG CCGTGCCCGA CTCCGCGCCG GCCCCGGGGG
CGGGCCCGGG CGGCGGGGGG CGGGTCTCTC CGGCGCACAT
AAAGGCCCGG CGCGACCGAC GCCCGCAGAC GGCGCCGGCC
HSV-1 p53RE-L 5’ AAACAAGGCCctt GCACATGCCG ----------
HSV-1 p53RE-S 5’ GAACTAGCGCggacc--------GGTCGATGCTT
HSV-1 TK 5’ TGCCTTGCCT-------------GGACTTGCCT
BCL6 5’ AGACAGTGCTTggggggtgattcGGGCTAGTCT
ABCA1 (MDR1) 5’ GGGCAGGAACgcgccggggcgt GGGCTGAGCA  -
GADD45A 5’ GAACATGTCT-------------AAGCATGCTG
HBV 5’ TTGCATGTATacaagct------AAACAGGCTT
MDM2 5’ GGTCAAGTTC-------------AGACACGTTC
VDR 5’ AGGTTAGATGtac TAACTAGTTT ----------
p73 5’ GTACTTGCCGtccgggga-----GAACTTGCAG
CASP6 5’ AGGCAAGGAGtttg---------AGACAAGTCT
CASP10 5’ AAACTTGCTGgttta--------AATCTTGGCT
Consensus 5’ RRRCWWGYYY(spacer) RRRCWWGYYY -----
Fig. 1. Identiﬁcation of candidate p53RE in the HSV-1 genome. (A) Schematic representation of the HSV-1 genome showing the locations of p53RE-L and p53RE-S in the
vicinity of the replication origins oriL and oriS. Arrows indicate the direction of transcription of the indicated genes. Not to scale. The sequences encompassing p53RE-L
(starting at position 62223) and p53RE-S (starting at position 131082) including the following pertinent elements are shown below the schematic: p53RE-L and p53RE-S are
boxed and in bold; the minimal oriL and oriS are in italics with the UL9 binding sites in bold; TATA boxes are underlined; TAATGARAT motifs are underlined with dashes;
arrowheads indicate the transcription start sites of UL29 and UL30 (p53RE-L) and ICP4 and ICP22/ICP47 (p53RE-S) as shown in the schematic. (B) Alignment of the putative
HSV-1 p53RE with known p53RE. The bases of the core motifs are underlined and spacer bases are shown in lowercase. Gaps were introduced following the spacer, where
present, to best align the ﬁrst and second core motifs. R, adenine or guanine; W, adenine or thymine; Y, cytosine or thymine.
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p53RE-S were identical to those that disrupt p53 binding in EMSA.
A vector containing the GADD45A p53RE was used as a positive
control while the non-recombinant plasmid was used to deter-
mine baseline reporter gene activity. Each of the reporter plas-
mids, including one encoding Renilla luciferase as an internal
control, were co-transfected with a p53 expression plasmid into
four recipient cell lines: African green monkey COS-7 ﬁbroblast-
like kidney cells, human colon cancer p53 knock-out cells HCT116
(p53/), human embryonic kidney cells HEK293, and African
green monkey kidney epithelial Vero cells. The results from dual
luciferase assays of cell lysates indicate that both p53RE-L and
p53RE-S were capable of conferring p53-dependent luciferase
reporter gene activity in COS-7 cells (Fig. 4A). However, reporter
gene activation was signiﬁcantly more robust with p53RE-S (40-
fold increase) than with p53RE-L (3-fold activation). In the
presence of 5-ﬂuorouracil (5-FU), a DNA damaging agent and
p53 co-activator (Bunz et al., 1999), reporter gene activity was
enhanced in all cases, with p53RE-S mediating higher activity than
p53RE-L as observed in the absence of 5-FU. Consistent with the
results obtained by EMSA, mutant p53RE-L and p53RE-S, exhibited
baseline reporter gene activity, thus conﬁrming the importance of
the C and G residues in the core motifs of p53RE-L and p53RE-S.
p53      - +     - +     - +
GADD45A p53RE-L p53RE-S
1 2 3 4 5 6
probe
Lysate            - +      +       +     - +       +     +    - +      +     +
PAb1801 + + +
GADD45A p53RE-L p53RE-S
p53
1   2
I
       - - -       - - - - - -
DO-1              - - +     - - - +      - - - +      -
GADD45A p53RE-L p53RE-S
Excess p53RE-S - - - - +  - - - - +  - - - - +
Excess p53RE-L - - - +  - - - - +  - - - - +  -
Excess GADD45 - - +  - - - - +  - - - - +  - -
p53 - +  +  +  +  - +  +  +  +  - +  +  +  +
Mock +  - - - - +  - - - - +  - - - -
p53         - +       - +      - + - +
mock      +       - +      - +       - +      -
p53RE-L
Mutant
p53RE-L
Mutant
p53RE-Sp53RE-S
1 2 3 4 5 6 7 8 9 10 11 12
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
1 2 3 4 5 6 7 8
Fig. 2. Binding of p53 to HSV-1 p53RE-L and p53RE-S in vitro. (A) EMSAwith 32P-labeled GADD45A, p53RE-L or p53RE-S oligonucleotides (1 ng) in the absence or presence of
150 ng puriﬁed p53 as indicated. The positions of free probe and p53–DNA complexes I and II are as indicated. (B) Immunoblot analysis of 5 mg of mock-transfected (lane 1) or
p53-transfected (lane 2) COS-7 cell lysates using DO-1 antibody. (C–E) EMSA was performed as described in Materials and methods. (C) p53–DNA complexes were formed
with 3 mg of p53-transfected COS-7 whole cell extract and the 32P-labeled GADD45A, p53RE-L or p53RE-S oligonucleotides (1 ng) as indicated. Antibodies DO-1 and pAb1801
were preincubated with the whole cell extracts for 1 h prior to the addition of the probe as indicated. (D) Reactions were performed as in (C) using either mock-transfected or
p53-transfected COS-7 whole cells extracts but in the presence of a 50-fold molar excess of unlabeled competitor oligonucleotide as indicated. (E) Reactions were performed
with either mock-transfected or p53-transfected COS-7 whole cells extracts using radiolabeled wild-type or mutant p53RE-L or p53RE-S as indicated. Only the portions of
the gels where protein–DNA complexes were evident are shown. The positions of p53–DNA complexes I and II are as indicated.
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Similar co-transfections were performed in the p53 knock-out
cells HCT116 (p53/), HEK293 cells, and Vero cells. In the absence
of p53, no reporter gene activationwas observed in HCT116 (p53 /)
cells (Fig. 4B). However, co-transfection with p53 led to 255-
and 647-fold increases in reporter gene activity with p53RE-L
and p53RE-S, respectively (Fig. 4B). Similarly, there were 30- and
2146-fold increases in p53 dependent activation of reporter
gene activity by p53RE-L and p53RE-S in HEK293 cells (Fig. 4C),
and corresponding increases of 32- and 221-fold in Vero
cells (Fig. 4D). The differential activity of p53RE-L and p53RE-S
between cell lines observed in these assays suggests that a cell
or tissue speciﬁc factor may inﬂuence the action of p53 on the
HSV-1 p53RE. Nonetheless, these results indicate that p53RE-L
and p53RE-S are functional p53RE, each of which is sufﬁcient to
confer p53-dependent transcriptional activation on a luciferase
reporter gene.
p53 represses p53RE proximal viral genes
To gain initial insight into whether p53 affects viral gene
expression in a manner that may be mediated via the HSV-1
p53RE, we utilized quantitative real-time PCR and immunoblot-
ting to examine the levels of ICP4 and ICP8, representing genes
proximal to p53RE-S and p53RE-L, respectively. Fig. 5 shows that
transcript levels of both ICP4 and ICP8 are signiﬁcantly reduced in
HSV-1 infected cells expressing p53. Thus, in p53 knock-out
HCT116 (p53/) cells, their expression is 5-fold higher than
in the parental (p53þ /þ) cells that express normal levels of p53
(Fig. 5A). Similarly, in HeLa cells ICP4 and ICP8 expression are
20-fold higher than in cells which over-express p53 via trans-
fection (Fig. 5B). These ﬁndings are substantiated by immunoblot-
ting which shows that ICP4 and ICP8 protein levels are reduced
when p53 is overexpressed (Fig. 6). Thus, HEK293 cells infected
with HSV-1 show robust expression of both ICP4 (both at 6 and
24 h post-infection) and ICP8 (at 24 h post-infection) (Fig. 6, lanes
p53RE-Sp53RE-L
220 bp
200bp100bp
200 bp
300 bp
400 bp
1  2    3    4    5    6  7    8  9    10   11   12  
UL30
265 bp
200 bp
300 bp
400 bp
500 bp
1 2 3 4 5 6
Fig. 3. Binding of p53 to p53RE-L and p53RE-S in HSV-1 infected Vero cells. ChIP
was performed as described in Materials and methods. As indicated, chromatin
(input) from mock-transfected/infected and p53-transfected/HSV-1-infected Vero
cells, and that precipitated with either p53-speciﬁc antibody DO-1 or non-speciﬁc
rat IgG, were used as templates for PCR to detect 200, 220 and 265 bp products
corresponding to p53RE-L (A), p53RE-S (A) and UL30 (B). Inverted images are
shown. The position of DNA standards are as indicated.
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Fig. 4. p53-dependent activation of a luciferase reporter gene by p53RE-L and p53RE-S. Reporter gene assays were performed as described in Materials and methods in COS-
7 (A), HCT116 (p53/) (B), HEK293 (C) and Vero (D) cells transfected with the combinations of plasmids and treated with 5-FU as indicated. mp53RE-S and mp53RE-L refer
to the mutant versions of the p53RE. Activity was calculated as the ratio of ﬁreﬂy to Renilla luciferase activity and expressed as relative light units (RLU). Each bar represents
the average of three independent experiments7standard deviation.
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2 and 5) while their expression is barely detectable upon co-
transfection with p53 (Fig. 6, lanes 3 and 6). β-actin was used as a
loading control (Fig. 6, bottom panel). Collectively, these data
indicate that p53 has a repressive effect on ICP4 and ICP8.
Discussion
The molecular mechanisms by which p53 regulates target
genes are complicated and remain elusive. The mechanisms for
p53 action appear to fall into two general categories: p53RE-
dependent and p53RE-independent. In the ﬁrst case, p53 mediates
transcriptional control by binding to p53RE as a tetramer and
subsequently recruiting diverse transcriptional co-regulators in
response to distinct genetic stimuli. Alternatively, p53 is reported
to regulate target genes via protein–protein interactions or in
response to post-translational modiﬁcation including phosphory-
lation, acetylation, ubiquitination, and/or methylation (Beckerman
and Prives, 2010).
To date, over one hundred and sixty-two p53RE have been
published and about a quarter of themwere found to be repressive
elements (Riley et al., 2008; Wang et al., 2009). Due to the
degeneracy of the p53 binding motif, each p53RE displays varia-
tions in both the core motif sequence and in the spacer length.
Most p53RE exist in the promoters and introns of cellular target
genes. p53 is known to have differential effects on several viral
systems. Not considering our current ﬁndings, only three other
conserved p53RE have been characterized in viral systems includ-
ing in the enhancer of hepatitis B virus (50 TTGCATGTATacaagc-
tAAACAGGCTT) (Ori et al., 1998), in the non-coding region of
human papillomavirus 77 (50 AAACATGTTTGCAAATCCCC) (Purdie
et al., 1999), and in the HSV-1 thymidine kinase gene promoter (50
TGCCTTGCCTGGACTTGCCTGGCCTTGCCTTT) (Yuan et al., 1993).
Additionally, it has been reported that p53 can bind to atypical
viral DNA elements such as the GC boxes of the simian virus 40
early promoter (Bargonetti et al., 1991) and the long terminal
repeat of human immunodeﬁciency virus-1 (Gualberto et al.,
1995). The case of human immunodeﬁciency virus-1 is particularly
unusual in that its p53RE (50 GCCCTGACGTGTCCCC) is not only
located within the Tax-responsive element but also overlaps with
a cAMP-responsive element. Moreover, during infection by human
immunodeﬁciency virus-1, cytomegalovirus, Ab-murine leukemia
virus, adenovirus, Epstein Barr virus, rift valley fever virus, and
simian virus 40, it has been observed that p53 may undergo
extensive post-translational modiﬁcations and participate in pro-
tein–protein interactions that affect target viral proteins (Lazo and
Santos, 2011). These actions of p53 in viral infection not only
display great mechanistic diversity, but may also provide crucial
insight into virus–host cell interactions.
Here we provide evidence for two novel types of functional
p53RE in a viral genome, namely that of HSV-1. The HSV-1 p53RE
are located in the vicinity of the replication origins oriL and oriS. In
HSV-1 strain KOS p53RE-L is situated at nucleotides 62608–62630
within the UL29–UL30 intergenic region, while p53RE-S is located
in the c repeats at nucleotides 131119–131144 and 146713–146738,
ﬂanked by the critical IE genes ICP4 and ICP22 or ICP47. Analysis
of the sequences of p53RE-L (50 AAACAAGGCCcttGCACATGCCG)
and p53RE-S (50 GAACTAGCGCggaccGGTCGATGCTT) reveals that
p53RE-L represents a perfect match to the consensus with a 3 bp
spacer between the two core p53 binding motifs, whereas p53RE-
S has an extra G in the second motif and a 5 bp spacer.
We observed binding of p53 to both p53RE-L and p53RE-S,
in vitro using EMSA, and in HSV-1 infected cells in vivo via ChIP.
Moreover, both HSV-1 p53RE are functional based on their ability
to activate reporter gene expression. Based on our EMSA results,
p53 binds to p53RE-L with a higher apparent afﬁnity than to
p53RE-S. Despite the apparently lower afﬁnity for p53RE-S and its
divergence from the consensus, in all four cell lines tested, p53RE-
S was signiﬁcantly more active in the reporter gene assay than
p53RE-L. Moreover, we found that reporter gene activation by
p53RE-L and p53RE-S was markedly cell type-dependent, with the
highest activity observed for p53RE-L in HCT116 (p53/) cells
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Fig. 5. Repression of ICP4 and ICP8 gene expression by p53. Quantitative real-time
PCR analysis of ICP4 and ICP8 gene expression was performed as described in
Materials and methods. (A) p53/ HCT116 (solid) and parental p53þ /þ (empty)
cells. (B) Mock-transfected (solid) and p53-transfected (empty) HeLa cells. The
results obtained for ICP4 and ICP8 were normalized to human glyceraldehyde
phosphate dehydrogenase expression, and are shown relative to the values
observed in HCT116 (p53/) (A) and mock-transfected HeLa cells (B) which were
assigned values of 1.0. Each bar represents the average of 3 independent experi-
ments7standard deviation.
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Fig. 6. Repression of ICP4 and ICP8 protein expression by p53. Immunoblot
showing ICP4, ICP8, p53 and β-actin levels in mock-infected/transfected and HSV-
1-infected/p53-transfected HEK293 cells. Where indicated, cells (3105) were
transfected with 2 mg pC53-SN. 24 h post-transfection cells were infected with
HSV-1 at a moi of 10 as indicated. Cells were harvested at the indicated times post-
infection. 20 mg of cell lysates were resolved by SDS-PAGE and analyzed by
immunoblotting as described in Materials and methods. Each panel represents
the area of the gel corresponding to ICP4, ICP8, p53 and β-actin as indicated. β-actin
was used as a loading control.
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and p53RE-S in HEK293 cells. Together, these data suggest that the
length of the spacer may inﬂuence p53RE activity, but that there
may also exist cell-type speciﬁc interactions with host proteins
that may affect the ability of p53 to exert its biologic actions. While
p53RE-L and p53RE-S are closest to the UL30 and ICP4 transcrip-
tion start sites, respectively, it is yet to be established which genes
might be the actual targets for regulation by p53 and whether they
are activated or repressed. Therefore, the possible effects of p53 on
the expression of UL29, UL30, ICP4, ICP22 or ICP47 and other genes
warrants further study. Moreover, given their location, effects of
these p53RE on the initiation of HSV-1 DNA replication at oriL and/
or oriS should also be entertained.
In this regard, our initial data indicate that in several cell lines,
p53 represses the expression of ICP8 and ICP4, that are proximal
to p53RE-L and p53RE-S, respectively. While further studies to
delineate the underlying mechanisms are necessary, the ﬁndings
raise the interesting notion that p53 has the ability to shut down
the expression of critical viral regulatory proteins and thereby
prevent a lytic replication cycle to perhaps favor the establishment
of latency. Our results are consistent with a previous report by
Yuan et al. (1993) in which the p53RE in the HSV-1 thymidine
kinase gene promoter binds p53 and is involved in the repression
of thymidine kinase gene expression.
Several groups have demonstrated that ectopic p53 expression
can result in cell-cycle arrest or apoptosis via generally established
pathways (Amundson et al., 1998; Smith et al., 2003) including in the
following cell lines: the myeloid leukemia line M1 (Yonish-Rouach
et al., 1991), osteosarcoma lines (Diller et al., 1990), colorectal
carcinoma lines SW480 and SW837 (Baker et al., 1990), post-
mitotic neurons (Slack et al., 1996), and HeLa (Haupt et al., 1995). In
the case of HeLa cells, two distinct p53-dependent apoptotic path-
ways have been proposed, either relying on p53RE-speciﬁc transacti-
vation or independent of p53RE sequences (Haupt et al., 1995). So
while it is possible that ectopic expression of p53 in our transient co-
transfections may have elicited such responses, albeit without per-
forming a quantitative evaluation for apoptosis or cell-cycle markers,
no morphological features associated with cell death were observed
by microscopic examination of COS-7, HEK293, HeLa, Vero, and
HCT116 cell lines under our experimental conditions. Therefore, in
our transient co-transfections, using the luciferase reporter gene
assay with the empty reporter plasmid (pLucMCS) and the GADD45A
p53RE as negative and positive controls, respectively, under the
speciﬁed conditions, the differential effects observed on reporter
gene activity should be attributed uniquely to the HSV-1 p53RE.
Nevertheless, it is possible that p53RE independent mechanisms also
operate including the possibility that ectopic expression of p53 in
these cell lines impacts gene expression by other means, e.g.
chromatin changes. Moreover, it is possible that the known effects
on p53 of transforming factors (e.g. SV40 T antigen) expressed in
some of the cell lines used in our studies, may inﬂuence our ﬁndings.
To this extent, Table 1 summarizes the p53 status of the various cell
lines used in this study and the possible impact of antigen expression.
However, just as in the case of cell-cycle arrest and apoptosis
discussed above, our conclusions are based on absolute differences
in reporter gene activity relative to the controls such that, under the
speciﬁed conditions, the ﬁndings should be attributed uniquely to the
HSV-1 p53RE.
The current understanding regarding the expression of the ﬁve
HSV-1 IE genes, ICP0, ICP4, ICP22, ICP27, and ICP47, includes the
dependency on the viral transactivator VP16, a component of the
viral tegument protein that forms a transcriptional regulatory
complex with Host Cell Factor-1 and cellular protein Oct-1 to bind
to consensus 50-TAATGARAT sequences in IE gene promoters
(Wysocka and Herr, 2003; Kristie et al., 2009). Our discovery that
p53RE-S is located between ICP4 and ICP22, may provide a novel
additional mechanism for regulating HSV-1 IE gene expression.
In conclusion, we have demonstrated the presence of two novel
functional p53RE in the vicinity of the replication origins in the
HSV-1 genome. Importantly, we also show that p53 represses
the expression of ICP4 and ICP8 which are in direct proximity to
p53-RE-S and p53RE-L, respectively, presumably in a mechanism
mediated by the viral p53RE, providing initial insight into the
possible effects of p53 on the expression of vital HSV-1 functions
and therefore on its replication. While the present data provide
some molecular evidence to support a regulatory role for p53 in
HSV-1 infection, further studies assessing the functional role of
these elements and the underlying mechanisms, taking into
account their genomic context and their potential interaction with
other transcription factors, are clearly merited.
Materials and methods
Reagents
p53 speciﬁc antibodies DO-1 and PAb1801 were purchased
from Santa Cruz Biotechnology, Dallas, TX and Delta Biolabs,
Gilroy, CA, respectively. Peroxidase-conjugated goat anti-mouse
IgG, β-actin antibody and ICP4 antibody were from Santa Cruz
Biotechnology. ICP8 antibody was as previously described (White
and Boehmer, 1999). Cells were transfected using the Express-In
transfection reagent (Thermo Scientiﬁc, Lafayette, CO). Plasmids
totaling 1.0 mg were diluted into 25 ml serum-free medium and
mixed with 25 ml serum-free medium containing 3 ml Express-In
reagent. Following a 30 min incubation at room temperature, the
DNA and Express-In mixtures were added to cells and incubated
for 48 h. Protein concentrations were determined by the BCA assay
(Pierce Biotechnology, Rockford, IL) according to the manufac-
turer's directions.
Cell culture and virus
COS-7, HeLa and Vero cells were grown in DMEM containing
10% fetal bovine serum (FBS). Parental (p53þ /þ) and p53 knock-
out (p53 /) HCT116 cells were cultured in McCoy's 5A medium
supplemented with 10% fetal bovine serum. HEK293 cells were
Table 1
Pertinent properties of cell lines used in this study.
Cell line Cell type p53 Genotype Expressed antigen Effects of antigen expression
COS-7 African green monkey kidney ﬁbroblast Wild-type SV40 T antigen SV40 T antigen inhibits p53 binding to DNA and reduces
p53-mediated transcriptional activity (Jiang et al., 1993).
HCT116 (p53þ /þ) Human colorectal carcinoma Wild-type N/A
HCT116 (p53/) Human colorectal carcinoma Knock-out N/A
Vero African green monkey kidney ﬁbroblast Wild-type N/A
HEK293 Human embryonic kidney epithelium Wild-type Adenovirus-5 E1B E1B inactivates p53 function (Yew and Berk, 1992).
HeLa Human cervical carcinoma Wild-type HPV-18 E6 E6 inhibits p53 DNA binding and affects its phosphorylation
(Ajay et al., 2012; Thomas et al., 1995; Thomas et al., 1996).
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maintained in MEM containing 10% FBS. The experiments per-
formed in these studies used HSV-1 strain KOS.
Plasmid construction
The following synthetic oligonucleotides and their comple-
ments were obtained from IDT DNA (Coralville, IA): GADD45A
p53RE (50 AGCTTGAACATGTCTAAGCATGCTGA), p53RE-L (50 AGCT-
TAAACAAGGCCCTTGCACATGCCGA), p53RE-S (50 AGCTTGAAC-
TAGCGCGGACCGGTCGATGCTTA), mutant p53RE-L (50 AGCTTAAA
AAATGCCCTTGCAAATTCCGA) and mutant p53RE-S (50 AGCTT-
GAAATATCGCGGACCGGTAGATTGCTTA). Base substitutions relative
to the wild-type sequences of p53RE-L and p53RE-S are shown in
italics. Each oligonucleotide also contained terminal bases corre-
sponding to the overhangs of HindIII and BglII at the 50 and 30 ends,
respectively. Oligonucleotide pairs were annealed and inserted
into the HindIII and BglII sites of pLuc-MCS (Stratagene Corp., La
Jolla, CA). The integrity of each resulting reporter plasmid was
conﬁrmed by DNA sequencing. The p53 expression vector, pC53-
SN, was a generous gift from Dr. Curtis Harris at the National
Cancer Institute (Huo et al., 2001).
Immunoblotting
For immunoblot analyses, cultured cells were harvested,
washed three times with PBS, and resuspended in KETD-0.3 buffer.
After sonication, lysates were centrifuged at 13,000 rpm for 15 min
at 4 1C and supernatants collected. The speciﬁed amounts of cell
lysate were resolved by 0.1% SDS, 7.5% PAGE, followed by transfer
to Immun-Blot PVDF membrane (Bio-Rad, Hercules, CA). The
resulting membrane was blocked with 5% milk in TBST for 1 h
and incubated with primary antibody in 5% milk TBST at 4 1C
overnight. The membrane was then washed four times with TBST
and incubated with peroxidase-conjugated goat anti-mouse IgG
secondary antibody for 1 h at room temperature. Visualization of
antibody complexes was performed using an ECL kit according to
the manufacturer instructions (GE Healthcare, Pittsburgh, PA).
p53 protein expression and puriﬁcation
The p53 expression vector pFLAG-p53 (generous gift from
Dr. Robert G. Roeder, Rockefeller University, New York, NY (Gu and
Roeder, 1997)) was transformed into E. coli BL21(pLysS). p53
expression was induced with 0.3 mM isopropyl β-D-thiogalacto-
side at 37 1C for 3 h and the cell pellet suspended in extraction
buffer (10 mM Tris–HCl, pH 8.0, 1 mM EDTA, 0.3 mM zinc acetate,
0.3 M KCl, 10% glycerol, 5 mM DTT, 0.1 mM phenylmethylsulfonyl
ﬂuoride, 15 mg/ml aprotinin, 1 mg/ml leupeptin, and 1 mg/ml pep-
statin A) with sonication. p53 was immunoprecipitated with
anti-Flag M2-agarose beads (Sigma-Aldrich, St. Louis, MO) and
centrifugation for 1 min at 3000 rpm. The beads were washed
twice with TBS (50 mM Tris–HCl pH 7.4, 150 mM NaCl) and p53
eluted by incubating the beads for 1 h at 4 1C with TBS containing
150 ng/ml 1 Flag peptide (Sigma-Aldrich, St. Louis, MO). The
purity and authenticity of the eluted protein were conﬁrmed
by Coomassie Blue staining and immunoblotting with the p53-
speciﬁc monoclonal antibody DO-1 (data not shown).
Electrophoretic mobility shift assay
Synthetic double-stranded p53RE oligonucleotides correspond-
ing to the sequences above were labeled with [α-32P]dGTP
(3000 Ci/mmol) with the Klenow fragment of DNA polymerase
(Thermo Scientiﬁc, Pittsburgh PA). EMSA was performed with
150 ng of puriﬁed p53 or 3 mg of whole cell extracts of COS-7
cells that were either mock-transfected or transfected with the
pC53-SN expression vector, as indicated. Cells were harvested,
washed three times with phosphate-buffer saline (PBS) (136 mM
NaCl, 26 mM KCl, 8 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.2), and
resuspended in KETD-0.3 buffer (10 mM Tris–HCl, pH 7.6, 1 mM
EDTA, 300 mM KCl, 10% glycerol, 1 mM DTT, 0.1 mM phenyl-
methylsulfonyl ﬂuoride, 15 mg/ml aprotinin, 1 mg/ml leupeptin,
and 1 mg/ml pepstatin A). After sonication, lysates were centri-
fuged at 16,000 rpm for 30 min at 4 1C. Supernatants were
collected, divided into small aliquots, and stored at 80 1C. For
the EMSA, puriﬁed p53 or lysate was combined with DNA binding
buffer (10 mM Tris–HCl, pH 7.6, 100 mM KCl, 2 mg of bovine serum
albumin, 1 mg of poly(dI:dC)) and incubated with 1 ng 32P-labeled
probe for 30 min in a 20 ml reaction volume. The reaction mixtures
were resolved through 4% non-denaturing TBE-polyacrylamide
gels, dried, and exposed for autoradiography.
Chromatin immunoprecipitation assay
Vero cells were seeded at 1.5106 cells/100 mm dish and
transfected with pC53-SN. Thirty-six hour post-transfection, cells
were infected with HSV-1 for 3 h at a multiplicity of infection
(moi) of 3. Mock-transfected/infected cells were used as a negative
control. The ChIP assay was performed using the EMD Millipore
ChIP assay kit (Billerica, MA) essentially according to the manu-
facturer's instructions. In brief, cells were cross-linked with
formaldehyde for 10 min at 37 1C. The cross-linking was termi-
nated by the addition of glycine followed by 5 min at 37 1C. Cells
were harvested and lysed. After 10 min on ice, the mixtures were
sonicated 10 times at 30 s on ice, to shear the DNA to lengths
between 200 and 1000 bp. The sonicated mixtures were centri-
fuged for 10 min at 13,000 rpm at 4 1C, and the supernatants
transferred to new tubes. To reduce non-speciﬁc background
binding, the mixtures were precleared with salmon sperm DNA/
protein A/G-agarose beads for 1 h at 4 1C with rotation. The
precleared chromatin supernatant was collected by centrifugation.
Ten percent of the precleared chromatin was used as input control
for subsequent PCR. The precleared chromatin was then incubated
overnight at 4 1C with rotation with 2 mg of p53-speciﬁc DO-1
antibody or 2 mg of goat anti-rat IgG. Immunoprecipitation was
achieved by adding salmon sperm DNA/protein A/G-agarose beads
for 90 min at 4 1C with rotation. Immune complexes were
obtained by repeated centrifugation and washing. Bound chroma-
tin was eluted and protein–DNA cross-links were reversed by
heating at 65 1C overnight. Following proteinase K digestion, DNA
was extracted with phenol–chloroform and precipitated with
glycogen. PCR (35 cycles: denaturing at 95 1C for 3 min, annealing
at 54 1C for 30 s, and extension at 72 1C for 1 min) was performed
to detect p53RE-L (forward primer 50-ACGCGAATAAACCGGGCCGC
and reverse primer 50-TGTTCCCACCCGAACCCCTA), p53RE-S (for-
ward primer 50-GGACGTAGCACGGTAGGTCA and reverse primer
50-GCCAGAGACAGACCGTCAGA) and a non-speciﬁc target corre-
sponding to nucleotides 64416–64680 in the UL30 gene (forward
primer 50-GCTACAAGCTCAACGCCGTG and reverse primer 50-AGG-
CACGTAAAGACGCGGAT) to generate products of 200, 220 and
265 bp, respectively. PCR products were detected by electrophoresis
through 2% agarose gels followed by ethidium bromide staining.
Transcriptional activity assay
The speciﬁed mammalian cell lines were seeded in 24-well
plates at a density of 8104 cells/well in 1 ml of the appropriate
medium plus 10% fetal bovine serum. After 6 h, cells were co-
transfected with 250 ng of the reporter plasmid to be tested, along
with 1 ng pRL-CMV, 250 ng pC53-SN and 500 ng of pTZ18U
plasmid as carrier DNA. Transfected cells were incubated for
48 h with or without 5-FU (1 μM) treatment. Thereafter, cells
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were washed twice with PBS and lysed with 100 ml passive lysis
buffer (Dual luciferase assay kit, Promega Corp., Madison, WI).
Fireﬂy and Renilla luciferase activities were measured sequentially
for each lysate using a Sirius Luminometer (Pforzheim, Germany)
and a Dual Luciferase assay kit (Promega Corp. Madison, WI) as per
the manufacturer's instructions. The ratio of ﬁreﬂy to Renilla
luciferase activity was calculated to normalize for transfection
efﬁciency.
Quantitative real-time PCR
HCT116 (parental (p53þ /þ) and p53 knock-out (p53/)) and
HeLa cells were seeded at 6105 cells/60 mm plate and infected with
HSV-1 at moi of 1. Total RNA were extracted using an Aurum total
RNA Mini kit (Bio-Rad, Hercules, CA) according to the manufacturer's
instructions. First-strand cDNA were synthesized from 2.0 mg total
RNA using an iScript cDNA synthesis kit (Bio-Rad Laboratories,
Hercules, CA) according to the manufacture's protocol. Two micro-
liters of each cDNA synthesis reaction was used as template in 20 ml
PCR reactions containing 10 ml PerfeCTa SYBR Green FastMix (Quanta
biosciences, Gaithersburg, MD) and 1 ml primers (18 mM). Reactions
were performed in 96-well PCR plates using a 7500 Fast detection
system (Applied Biosystems Inc., Foster City, CA). Reactions were
performed with the following primer pairs: human glyceraldehyde
phosphate dehydrogenase forward primer 50-ACAACTTTGGTATCGTG-
GAAGGAC and reverse primer 50-CAGGGATGATGTTCTGGAGAGC;
HSV-1 ICP4 forward primer 50-CGACACGGATCCACGACCC and
reverse primer 50-GATCCCCCTCCCGCGCTTCGTCCG; HSV-1 UL29 for-
ward primer 50-GTGTTGGGGTTGAGCATCAG-30 and reverse primer
50-TCCGCCGCCGAGGTTC-30. All results were normalized to the activ-
ity observed with human glyceraldehyde phosphate dehydrogenase.
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